CA
DNA icon

Clearstead Advisors’s Ginkgo Bioworks DNA Stock Holding History

Clearstead Advisors’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.53K Buy
457
+455
+22,750% +$3.81K ﹤0.01% 2227
2026
Q1 		$13 Hold
2
– – ﹤0.01% 2222
2025
Q4 		$17 Hold
2
– – ﹤0.01% 2698
2025
Q3 		$30 Sell
2
-500
-100% -$5.98K ﹤0.01% 3004
2025
Q2 		$5.65K Sell
502
-7
-1% -$54 ﹤0.01% 2071
2025
Q1 		$2.9K Hold
509
– – ﹤0.01% 1832
2024
Q4 		$5K Hold
509
– – ﹤0.01% 1719
2024
Q3 		$4.15K Sell
509
-1
-0.2% -$10 ﹤0.01% 1740
2024
Q2 		$6.82K Buy
510
+500
+5,000% +$14.9K ﹤0.01% 1625
2024
Q1 		$345 Buy
10
+2
+25% +$104 ﹤0.01% 1477
2023
Q4 		$507 Hold
8
– – ﹤0.01% 1461
2023
Q3 		$543 Buy
8
+2
+33% +$160 ﹤0.01% 1411
2023
Q2 		$465 Sell
6
-48
-89% -$2.84K ﹤0.01% 1305
2023
Q1 		$2.86K Hold
54
– – ﹤0.01% 1085
2022
Q4 		$3.63K Hold
54
– – ﹤0.01% 1019
2022
Q3 		$7K Hold
54
– – ﹤0.01% 928
2022
Q2 		$5K Hold
54
– – ﹤0.01% 996
2022
Q1 		$9K Buy
+54
New +$10.5K ﹤0.01% 997

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Clearstead Advisors's DNA Position: Q2 2026 in Review

Clearstead Advisors increased its Ginkgo Bioworks (DNA) stake by 22,750% in Q2 2026, buying an estimated $3.81K and bringing the position to 457 shares worth $4.53K. The position accounts for ﹤0.01% of the portfolio, ranked #2227.

Clearstead Advisors first reported a position in DNA in Q1 2022 and has held it in 18 quarters since. The position peaked at $9K in Q1 2022. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Clearstead Advisors held 457 shares of Ginkgo Bioworks worth $4.53K as of Q2 2026.
  • Clearstead Advisors bought 455 Ginkgo Bioworks shares in Q2 2026, an estimated $3.81K.
  • Ginkgo Bioworks made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2227 holding.
  • Clearstead Advisors first reported a position in Ginkgo Bioworks in Q1 2022 and has held it in 18 quarters since.
  • Clearstead Advisors's Ginkgo Bioworks position peaked at $9K in Q1 2022.
  • 184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.